1. Home
  2. Analysis
  3. Ramipril
  4. Central-obesity

Ramipril and Central obesity - a phase IV clinical study of FDA data

Summary:

Central obesity is reported as a side effect among people who take Ramipril (ramipril), especially for people who are female, 60+ old, also take Metformin, and have Metastases to peritoneum.

The phase IV clinical study analyzes which people have Central obesity when taking Ramipril. It is created by eHealthMe based on reports of 144,209 people who have side effects when taking Ramipril from the FDA, and is updated regularly.

What is Ramipril?

Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 147,397 Ramipril users. Check the latest studies of Ramipril.

What is Central obesity?

Central obesity (belly fat) is found to be associated with 161 drugs and 252 conditions by eHealthMe. Check the latest studies of Central obesity.

On Jul, 12, 2026

144,209 people reported to have side effects when taking Ramipril.
Among them, 33 people (0.02%) have Central obesity.

Could Ramipril cause Central obesity?

Among these 33 people:

What is the gender of people who have Central obesity when taking Ramipril? *

  • female: 78.26 %
  • male: 21.74 %

What is the age of people who have Central obesity when taking Ramipril? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 3.7 %
  • 30-39: 0.0 %
  • 40-49: 18.52 %
  • 50-59: 3.7 %
  • 60+: 74.07 %

What are other drugs people take besides Ramipril? *

  1. Metformin: 26 people, 78.79%
  2. Femara: 15 people, 45.45%
  3. Rabeprazole: 14 people, 42.42%
  4. Magnesium: 6 people, 18.18%
  5. Furosemide: 5 people, 15.15%
  6. Ergocalciferol: 5 people, 15.15%
  7. Sitagliptin: 5 people, 15.15%
  8. Atrovent: 5 people, 15.15%
  9. Pregabalin: 5 people, 15.15%
  10. Breo Ellipta: 4 people, 12.12%

What are other side effects people have besides Central obesity? *

  1. Abdominal Distension: 18 people, 54.55%
  2. Hypotension (abnormally low blood pressure): 18 people, 54.55%
  3. Weakness: 18 people, 54.55%
  4. Postmenopausal Haemorrhage (post-menopausal bleeding): 18 people, 54.55%
  5. Carbohydrate Antigen 125 Increased: 18 people, 54.55%
  6. Dyspnea (difficult or laboured breathing): 6 people, 18.18%
  7. Fatigue (feeling of tiredness): 6 people, 18.18%
  8. Asthma: 5 people, 15.15%
  9. Urination - Excessive At Night: 5 people, 15.15%
  10. Upper Respiratory Tract Infection: 5 people, 15.15%

What are the existing conditions these people have? *

  1. Metastases To Peritoneum (cancer spreads to peritoneum): 18 people, 54.55%
  2. Sinusitis (inflammation of sinus): 1 person, 3.03%
  3. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 3.03%
  4. Rheumatoid Factor Positive: 1 person, 3.03%
  5. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 3.03%
  6. Hiv Test Positive: 1 person, 3.03%
  7. Hiv Infection: 1 person, 3.03%
  8. Anti-Cyclic Citrullinated Peptide Antibody Positive: 1 person, 3.03%

* Approximation only. Some reports may have incomplete information.

Do you take Ramipril and have Central obesity?

- Check whether Central obesity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ramipril:

Central obesity treatments and more:

How severe was Central obesity and when was it recovered:

Expand to all the drugs that have ingredients of ramipril:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ramipril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Central obesity:

Browse all the conditions that are associated with Central obesity:

How the study uses the data?

The study uses data from the FDA. It is based on ramipril (the active ingredients of Ramipril) and Ramipril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.